FDA Concerned With Side Effect of Oscient Drug
Oscient is seeking FDA approval for a five-day version of the drug meant to treat acute sinus infections. The leading ingredient in Factive, gemifloxacin, is already approved as a seven-day treatment for community-acquired pneumonia and a five-day treatment for certain cases of chronic bronchitis.
Sinusitis is an inflammation of the sinuses...
To view the full article, register now.